Senior co-investigator/researcher with 7 years post doctoral experience leading pharmacological driven research focused on the utilisation of nanoengineering technology, manipulating and exploiting interactions of excipient and particle properties to produce receptor specific cell target drug loaded nano-carriers, specifically solid drug nanoparticles, stabilised emulsions and polydendrons with the aim of enhancing conventional anti-infective therapies whilst increasing safety through reduced toxicity. In addition, I lead the investigation into identifying the mechanisms involved in the observed reduction of in vitro / in vivo / ex vivo cytotoxicity, increased permeability, accumulation, tissue distribution and efficacy of our patented nanoformulated anti-infectives. I am author on high impact peer reviewed journal articles encompassing regulation of drug disposition, nanomedicine and pharmacology. I am a reviewer for several international journals and research funding councils, including the Medical Research Council (MRC, UK). In addition to ISSX membership, I am a sponsored member of the American Association for the Advancement of Science (AAAS) and an executive member for The British Society for Nanomedicine.